title: [A patient with of metastatic breast cancer with a well-controlled quality of life using S-1 therapy as first-line chemotherapy].
abstract: We experienced a case of endocrine therapy-resistant recurrent breast cancer with liver and bone metastases, treated with S-1 as first-line chemotherapy and maintaining a good quality of life. The patient was a 31-year-old premenopausal woman. She was diagnosed with cancer of the left breast(T1(18mm), N0, M(-))and underwent breast-conserving surgery, sentinel lymph node biopsy, and radiation therapy in August 2002. As there was hormone sensitivity, she was treated with LHRH analog for 3 years and tamoxifen for 5 years as adjuvant therapy. After her first childbirth, she had a recurrence of liver and bone metastases. After treatment with endocrine therapy failed, an oral administration of S-1 was initiated as first-line chemotherapy considering her QOL. She received 8 months of S-1 therapy with no severe adverse reactions and maintained a high quality of life. Treatment with S-1 is thought to be useful for first-line chemotherapy if the treatment demonstrates a therapeutic equivalence with taxane on patients' overall survival.
authors.affiliation: Dept. of Breast Surgery, Sagara Hospital, Hakuaikai Medical Corporation, Japan.
authors.forename: Shugo
authors.initials: S
authors.lastname: Tamada
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Sagara
authors.forename: Shinichi
authors.initials: S
authors.lastname: Baba
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Sagara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yotsumoto
authors.forename: Ayami
authors.initials: A
authors.lastname: Matsukata
authors.forename: Mitsutake
authors.initials: M
authors.lastname: Andou
authors.forename: Yoshiatsu
authors.initials: Y
authors.lastname: Sagara
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Rai
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D010094:Oxonic Acid / Q000627:therapeutic use*; D011788:Quality of Life; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid